Moderna (MRNA) return on equity (ROE)

Return on equity · fiscal 2025
-32.6%

Moderna (MRNA) earned a return on equity of -32.6% in fiscal 2025 (the year ended December 31, 2025). That is level with fiscal 2024. Figures as of 18 Nov 2026, 00:26 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-32.6%
Change on fiscal 2024
+0.0 pts
Highest on record
86.3%fiscal 2021
Lowest on record
-43.7%fiscal 2019
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Moderna return on equity (ROE), in more detail

Across the 8 fiscal years on record (2018–2025), the highest was 86.3% in fiscal 2021 and the lowest -43.7% in fiscal 2019. The fiscal 2025 figure is higher than in 43% of the 7 earlier fiscal years on record, whose median is -29.2%.

History · 8 fiscal years

Return on equity by fiscal year

Moderna return on equity (ROE), year by year

Moderna (MRNA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-32.6% 0.0 pts
2024-32.7% 1.4 pts up
2023-34.0% 77.8 pts down
202243.7% 42.5 pts down
202186.3% 115.4 pts up
2020-29.2% 14.6 pts up
2019-43.7% 18.6 pts down
2018-25.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Moderna and comparable companies
CompanyReturn on equityFiscal year
McKesson MCK17.7%2020
Sanofi SNY10.9%2025
Moderna MRNA-32.6%2025
HCA Healthcare HCA656.3%2020
GSK GSK34.9%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on MRNA

Moderna, figure by figure

Moderna (MRNA) overview: price, valuation and scorecardAll health care companies by market value

Moderna return on equity (ROE): questions and answers

What is Moderna's return on equity?

Moderna (MRNA) earned a return on equity of -32.6% in fiscal 2025 (the year ended December 31, 2025). That is level with fiscal 2024.

Is Moderna's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 43% of the 7 earlier fiscal years on record, whose median is -29.2%.

What are the highest and lowest return on equity figures on record for Moderna?

Across the 8 fiscal years on record (2018–2025), the highest was 86.3% in fiscal 2021 and the lowest -43.7% in fiscal 2019.

How is Moderna's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Moderna (MRNA) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/MRNA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.